ClinicalTrials.gg
Not yet recruitingNCT07592806CRISTELUpdated May 18, 2026

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation

An interventional study of Blood sample in Surgical Operation With Transplant of Whole Organ, sponsored by Hopital Foch. Not yet recruiting. Open to female participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Hopital Foch · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Ages
18 Years to 48 Years
Sex
Female
01

Study summary

The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Read the detailed description

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).

Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.

Among the unknowns that remain despite these registry data, the following should be noted:

Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);

Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;

Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);

The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;

The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);

Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?

Infant morbidity in the short and medium term.

To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).

The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.

Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

02

Conditions studied

  • Surgical Operation With Transplant of Whole Organ
03

In context

Lead sponsor

Hopital Foch is the lead sponsor of 215 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 48 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patient aged 18 years or older and of childbearing age
  • Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
  • Has a positive blood beta-hCG test result > 5 IU/L ("positive")
  • Has signed an form
  • Affiliated with a health insurance plan

Exclusion criteria

Exclusion Criteria:

  • Patient deprived of liberty or under legal guardianship
  • Patient refuses to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Other
    Adult female patients who have received a solid organ transplant

    Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.

    Other: Blood sample

Interventions

  • OtherBlood sample

    Two optional (non-mandatory) biological samples may be collected as part of this study: A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected. A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function).

06

What researchers measure

Primary outcomes

  1. The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).

    The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).

    Time frame: Annually over the 10-year study period

Secondary outcomes

  1. Rate of preeclampsia

    Rate of preeclampsia

    Time frame: Through study completion, an average of 1 year

  2. Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);

    Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);

    Time frame: 3 months and 12 months postopartum

  3. Live birth rate among transplanted mothers from the onset of pregnancy.

    Live birth rate among transplanted mothers from the onset of pregnancy.

    Time frame: through study completion, an average of 1 year

  4. Trajectory of serum creatinine levels

    Trajectory of serum creatinine levels

    Time frame: During pregnancy (up to 40 weeks if gestation)

  5. Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)

    Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)

    Time frame: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth

  6. Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.

    Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.

    Time frame: Day of delivery: Perioperative/Periprocedural

  7. Birth weight of the newborn (in grams)

    Birth weight of the newborn (in grams)

    Time frame: day of delivery

  8. Rate of spontaneous miscarriage

    Rate of spontaneous miscarriage

    Time frame: Through study completion, an average of 1 year

  9. Rate of cesarean section

    Rate of cesarean section

    Time frame: Through study completion, an average of 1 year

  10. Rate of prematurity

    Rate of prematurity

    Time frame: Through study completion, an average of 1 year

  11. Rate of intrauterine growth restriction

    Rate of intrauterine growth restriction

    Time frame: Through study completion, an average of 1 year

  12. the duration of hospital stay for both the mother and the newborn

    the duration of hospital stay for both the mother and the newborn

    Time frame: Through study completion, an average of 1 year

  13. incidence of biopsy-proven acute rejection up to 12 months postpartum;

    incidence of biopsy-proven acute rejection up to 12 months postpartum;

    Time frame: up to 12 months postpartum;

  14. incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.

    incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.

    Time frame: 3 months and 12 months postoartum

  15. Trajectory of proteinuria (protein-to-creatinine ratio)

    Trajectory of proteinuria (protein-to-creatinine ratio)

    Time frame: During pregnancy (up to 40 weeks if gestation)

  16. Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,

    Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,

    Time frame: During pregnancy (up to 40 weeks if gestation)

  17. Trajectory of anti-angiogenic factors during pregnancy

    Trajectory of anti-angiogenic factors during pregnancy

    Time frame: During pregnancy (up to 40 weeks if gestation)

  18. Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)

    Rate of maternal hospitalizations before delivery and in the postpartum period

    Time frame: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth

  19. Apgar score

    Apgar score

    Time frame: day of delivery

  20. Proportion of growth-restricted

    Proportion of growth-restricted

    Time frame: day of delivery and up 3 month postpartum

  21. Incidence of neonatal complications before the third month of life

    Incidence of neonatal complications before the third month of life

    Time frame: day of delivery and up 3 month postpartum

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2036, 120 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
May 18, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2036
CompletionEst.
Sep 1, 2036
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07592806
Lead sponsor
Hopital Foch
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2036 (estimated)
Completion
Sep 1, 2036 (estimated)
Last update
May 18, 2026

Study contacts

Sahar Pr SELLAMI JALLOULI, PhD
Contact
s.sellami-jallouli@hopital-foch.com
01 46 25 31 37
Alexandre Pr Hertig, MED
principal investigator · Foch Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion